Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer

Oncogene

Volumn 33, Issue 20, 2014, Pages 2589-2600

  Li, Q ^a   Yao, Y ^a   Eades, G ^a   Liu, Z ^a   Zhang, Y ^a   Zhou, Q ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

basal like breast cancer; cancer stem cells; ductal carcinoma in situ; microRNAs

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABCA10 PROTEIN; ALDEHYDE DEHYDROGENASE; ESTROGEN RECEPTOR ALPHA; INTERLEUKIN 6 RECEPTOR; KRUPPEL LIKE FACTOR 4; MICRORNA; MICRORNA 140; NOTCH2 RECEPTOR; SULFORAPHANE; TAMOXIFEN; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; WNT4 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL LIKE BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER STEM CELL; CELL ACTIVATION; CELL MATURATION; CELL RENEWAL; CONTROLLED STUDY; DOWN REGULATION; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTRACELLULAR SIGNALING; INTRADUCTAL CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL RESEARCH; TUMOR GROWTH;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE, TUMOR; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; ISOENZYMES; MICRORNAS; NEOPLASTIC STEM CELLS; RETINAL DEHYDROGENASE; SOX9 TRANSCRIPTION FACTOR;

EID: 84901241324     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.226     Document Type: Article

References (48)

1. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004; 96: 906-920. (Pubitemid 38868137
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. Cancer J Clin 2007; 57: 43-66
3. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev 2005; 14: 1008-1011
4. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002; 94: 1546-1555
5. Poller DN, Barth A, Slamon DJ, Silverstein MJ, Gierson ED, Coburn WJ et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 1154-1157
6. Solin LJ, Yeh I, Kurtz J, Fourquet A, Recht A, Kurske R et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation correlation of pathologic parameters with outcome of treatment. Cancer 1993; 71: 2532-2542. (Pubitemid 23100488
7. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16: 441-452. (Pubitemid 28135585
8. Fowble B, Hanlon A, Fein D, Hoffman J, Sigurdson E, Patchefsky A et al. Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS). Int J Radiat Oncol Biol Phys 1997; 38: 949-957. (Pubitemid 27353673
9. Lennington WJ, Jensen RA, Dalton LW, Page DL. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer 1994; 73: 118-124
10. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001; 28: 400-418. (Pubitemid 32762083
11. Houghton J. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomized controlled trial. Lancet 2003; 362: 95-102
12. Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J et al. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One 2010; 5: E10240
13. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768
14. Takebe N, Ivy SP. Controversies in cancer stem cells: Targeting embryonic signaling pathways. Clin Cancer Res 2010; 16: 3106-3112
15. Farnie G, Clarke R. Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev 2007; 3: 169-175. (Pubitemid 350129719
16. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866. (Pubitemid 44629897
17. Ruan K, Fang X, Ouyang G. MicroRNAs: Novel regulators in the hallmarks of human cancer. Cancer Lett 2009; 285: 116-126
18. Vrba L, Garbe JC, Stampfer MR, Futscher BW. Epigenetic regulation of normal human mammary cell type-specific miRNAs. Genome Res 2011; 21: 2026-2037
19. Farazi TA, Horlings HM, ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 2011; 71: 4443-4453
20. Volinia S, Galasso M, Sana ME, Wise TF, Palantini J, Huebner K et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA 2012; 109: 3024-3029
21. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem 2011; 286: 25992-26002
22. Lehmann U, Hasemeier B, Christgen M, Muller M, Romermann D, Langer F et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008; 214: 17-24
23. de Souza RS, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor a in breast cancer cells. Cancer Res 2010; 70: 9175-9184
24. Yang J, Qin S, Yi C, Ma G, Zhu G, Zhou W et al. MiR-140 is co-expressed with Wwp2-C transcript and activated by Sox9 to target Sp1 in maintaining the chondrocyte proliferation. FEBS Lett 2011; 585: 2992-2997
25. Takai D, Jones PA. The CpG island searcher: A new WWW resource. In Silico Biol 2003; 3: 235-240. (Pubitemid 37493047
26. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007; 38: 197-204. (Pubitemid 46096566
27. Zhou W, Jirstrom K, Johansson C, Amini R, Blomqvist C, Agbaje O et al. Long-Term survival of women with basal-like ductal carcinoma in situ of the breast: A population-based cohort study. BMC Cancer 2010; 10: 653
28. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com Xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 2000; 92: 1185a-1186a.
29. Tait LR, Pauley RJ, Santner SJ, Heppner GH, Heng HH, Rak JW et al. Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer 2007; 120: 2127-2134. (Pubitemid 46555849
30. Scribner KC, Behbod F, Porter WW. Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s). Oncogene 2012; 32: 2631-2639
31. Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis 2006; 27: 811-819
32. Hsu A, Wong C, Yu Z, Williams D, Dashwood R, Ho E. Promoter de-methylation of cyclin D2 by sulforaphane in prostate cancer cells. Clin Epigenetics 2011; 3: 3
33. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat M et al. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439: 84-88. (Pubitemid 43053633
34. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006; 439: 993-997. (Pubitemid 43292419
35. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988. (Pubitemid 36418143
36. Liu S, Clouthier S, Wicha M. Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia 2012; 17: 15-21
37. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro J et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression Distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64: 937-946
38. de Beça FF, Caetano P, Gerhard R, Alvarenga CA, Gomes M, Paraedes J et al. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol 2013; 66: 187-191
39. Guo W, Keckesova Z, Donaher J, Shibue T, Tischler V, Reinhardt F et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012; 148: 1015-1028
40. Ginestier C, Hur MH, Charafe-Jaufret E, Monville F, Dutcher J, Brown M et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567. (Pubitemid 350056407
41. Kao J, Salari K, Bocanegra M, Choi Y, Girard L, Gandhi J et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009; 4: E6146
42. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. In vitro propagation and transcriptional profiling of human mammary stem/ progenitor cells. Genes Dev 2003; 17: 1253-1270
43. Tsai H, Li H, Van Neste L, Cai Y, Robert C, Rassool F et al. Transient low doses of dna-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012; 21: 430-446
44. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603
45. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-647. (Pubitemid 40343076
46. Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L et al. Loss of Let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 2012; 7: E33729
47. Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J et al. MicroRNA-30a inhibits epithelial-To-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 2012; 130: 2044-2053
48. Yamashita S, Miyaki S, Kato Y, Yokoyama S, Sato T, Barrionuevo F et al. L-Sox5 and Sox6 enhance chondrogenic miR-140 expression by strengthening dimeric Sox9 activity. J Biol Chem 2012; 287: 22206-22215